LOS ANGELES/NEW YORK - Yahoo Inc has submitted a formal proposal to buy Hulu, joining a growing list of bidders for the video service owned by News Corp and Walt Disney Co, two sources with knowledge of the bid told Reuters on Friday.
FRANKFURT - New solar installations reached a fresh record of 7.5 gigawatts (GW) in Germany in 2011, playing into the hands of advocates for steeper cuts in tariff subsidies to reduce growth of solar power and the resulting higher costs for consumers.
Bristol to buy Inhibitex for hepatitis C treatment
(Reuters) - Bristol-Myers Squibb Co has agreed to acquire Inhibitex Inc for about $2.5 billion to gain access to its promising hepatitis C treatment, the companies said on Saturday.
At $26 per share, the deal is a huge 163 percent premium to Inhibitex's closing price of $9.87 on Friday.
Recent years have seen significant advances for treating hepatitis C - a serious liver disease that afflicts an estimated 180 million people worldwide - while setting off a scramble among large drugmakers to secure the most promising products.
The Bristol-Inhibitex deal comes on the heels of Gilead Sciences Inc's $11 billion acquisition in November of Pharmasset Inc, which has its own promsing hepatitis C therapies. That deal was at an 89 percent premium.
Inhibitex's lead asset is INX-189, an oral drug in Phase II or mid-stage development. Bristol envisions combining INX-189 with products in its own pipeline to create an all-oral regimen that would eliminate the need for interferons, which often cause flu-like side effects that lead many hepatitis C patients to stop or delay treatment.
Bristol expects the transaction to hurt earnings through 2016. That includes an expected hit to earnings per share of about 4 cents in 2012 and 5 cents in 2013.
Analysts on average expect Bristol to earn $2.01 per share in both 2012 and 2013, according to Thomson Reuters I/B/E/S.
(Reporting By Lewis Krauskopf; Editing by John O'Callaghan)
- Tweet this
- Share this
- Digg this